Addison's disease

Ali, having done some work with Bijay on Addison's disease presented this at a Thursday lunchtime to the DEVHC staff.

The first section is a general overview on Addison's disease, the second looking at the evidence for replacement steroid doses for patients with Addison's disease undergoing surgery and the last, looking at the short-synacthen tests performed in the hospital over the past three years.

Addison’s Disease

View more documents from PeninsulaEndocrine.

Torbay Mid-Foot Amputation Audit

The Torbay Foot team, have audited their mid-foot amputations in the two years to 2007. These are their results.

Mid Foot Amputations Torbay 2009

View more documents from PeninsulaEndocrine.

RD&E Exenatide Audit.

Pam Bowman, the academic F2 has audited the initial use of exenatide at the RD&E.

Exenatide, the first commercially available GLP-1 analogue, has been mentioned in the latest NICE guidelines for those with a BMI >35, an HbA1c >7.5%, on maximum oral metformin and sulphonylurea, who would otherwise be starting a high-cost medication.

NICE also mention criteria for success: a weight loss >5% at one year and improvement in HbA1c >1%

The audit is limited in scope as not many patients have been on the medication 6 months, let alone one year.

The interesting issues are that we are using it off-licence (i.e in those already on insulin) and that doesn't seem to influence outcome.

Here is the audit. Other peoples thoughts, experiences and comments would be useful... just use the comments link at the bottom of this post.

Exenatide Presentation

View more presentations from PeninsulaEndocrine.